NDASUBCUTANEOUSPOWDER
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
3/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 23h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOXZOGO (vosoritide) is a subcutaneous powder biologic developed by BioMarin Pharmaceutical, approved in November 2021. It is a C-type natriuretic peptide (CNP) analog receptor agonist designed to address skeletal dysplasia. The drug works by activating natriuretic peptide receptor B signaling to promote endochondral bone growth.
Peak15.8 years to LOE
Peak lifecycle status indicates the product is in active growth phase with mature commercial infrastructure, supporting robust field and commercial leadership teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Started Apr 2026
160 enrolled
Achondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Started Jul 2025
60 enrolled
Hypochondroplasia
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Started Jun 2025
140 enrolled
Hypochondroplasia
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Started Nov 2024
30 enrolled
Noonan Syndrome
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
Started Oct 2024
100 enrolled
Idiopathic Short Stature
Worked on VOXZOGO at BioMarin Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.